Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Earnings for Xilio Therapeutics, Inc. (XLO)
Earnings in 2023 (TTM): $-76,404,000
According to Xilio Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-76,404,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Xilio Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-76,404,000 | $-76,404,000 |
| 2022 | $-88,222,000 | $-87,295,000 |
| 2021 | $-75,800,000 | $-74,301,000 |
| 2020 | $-55,219,000 | $-55,219,000 |
| 2019 | $-17,311,000 | $-17,311,000 |